This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Results

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The benefits of interferon beta-1a treatment included:

  • reduction in relapse rates:
    • 27% for the 22 mcg group
    • 33% for the 44 mcg group

  • prolongation in the time to first relapse:
    • 3 months for the 22 mcg group
    • 5 months for the 44 mcg group

  • time to sustained progression was significantly longer in both treatment groups (p<0.05)

  • disease burden as assessed by T2-weighted MRI scans was significantly lower in both treatment groups

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.